German multinational pharmaceutical and life sciences company Bayer AG (ETR:BAYN) has opened a new Research and Innovation Center in the United States, the company announced on Wednesday.
Located at Kendall Square in Boston-Cambridge, Massachusetts, this 62,100 sq ft facility houses a new centre of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies.
In addition, a newly established research team will focus on leveraging chemical biology techniques to further advance the company's oncology drug development process.
Bayer's investment in the new facility amounts to USD140m.
Boston-Cambridge is home to approximately 1,000 biotechnology companies, with Kendall Square being the centre of pharmaceutical innovation on the East Coast of the US, Bayer said. The company is now present in four of the largest biotechnology hubs in the country: Boston, San Francisco, San Diego and Research Triangle Park, North Carolina.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients